Skip to main content

Vim3 and Mxi-2 Antibody

Ref-Nr: TA-3485, 4922


Kurzfassung

Liquid biopsy: preoperative marker for diagnosis and differentiation of benign and malignant renal carcinoma


Hintergrund

Kidney cancer is classified as malignant tumors originating from different renal cells with several subtypes. The cells of these subtypes can mimic a benign kidney tumor, called oncocytoma. The unequivocal differentiation is essential for planning the adequate operative procedure and the patient follow-up monitoring (which is not necessary for oncocytoma).


Problemstellung

To date, it is not possible to reliably differentiate between malignant subtypes and benign kidney tumors by means of the available antibody panel and imaging methods.


Lösung

The inventors found a splice isoform of Vimentin, namely Vimentin3 (Vim3), as an indicator of benign Oncocytoma. Renal cell carcinomas (RCCs) are negative for Vim3. Also discovered was a truncated variant of the protein MAPK p38, namely Mxi-2, which indicates RCC, including all subtypes. Oncocytoma, however, is negative for Mxi-2. Both markers are detectable by means of monoclonal antibodies directed against Vim3 and Mxi-2 in body fluids, such as urine, as well as in tissue.

Detection of both markers in urine makes it possible for the first time to provide urologist and oncologist a non-invasive test for a preoperative diagnosis so as to appropriately treat the patient and plan the follow-up.

The marker Vim3 is currently being validated. The test strip is under development. The ELISA is already working. The validation of the marker Mxi-2 is planned.  


Vorteile

  • novel approach: markers for non-invasive diagnosis of kidney tumors
  • optimized treatment and follow-up of patients due to an accurate and valid diagnosis and differentiation of benign kidney tumors and malignant renal carcinomas
  • markers also usable for routine medical checkup (persons aged 55 and above)
  • monoclonal antibodies designed for use
  • urine quick test in development

Anwendungsbereiche

The conception of the future product is to offer a two-step test: After recognising a suspicious event on ultrasonography, the resident urologist is able to test the urine of the patient with a test-strip or ELISA which combines both markers. If the kidney tumor is benign (Oncocytoma), Vim3 is detectable. In case of positive Mxi-2 detection, the tumor is malignant (RCC). No staining indicates no kidney tumor is present. After the surgery the result will be confirmed in the removed tumor tissue. The use in cancer screening is also conceivable.


Service

On behalf of the University of Cologne, PROvendis offers a patent license as well as a research collaboration with licensing option.


PROvendis GmbH

Dipl.-Biol. Kordula Kruber
+49.208 94105-30
kk@provendis.info
www.provendis.info
Adresse
Schloßstr. 11-15
45468 Mülheim an der Ruhr



Entwicklungsstand

Demonstrationsexemplar


Patentsituation

  • EP anhängig

Stichworte

Flüssigkeitsbiopsie, Urin, Urindiagnostik, Tumorgewebe, Teststreifen, ELISA, präoperativer Marker, Differentialdiagnose, nicht-invasiv, Unterscheidung zwischen gut- und bösartig, Nierentumor, Nierenzellkarzinom, Onkozytom, Niere, Antikörper, Vimentin, Vimentin3, MAPK p38, Mxi-2, Liquid biopsy, urine, urine diagnostics, tumor tissue, diagnostic medical dipstic, ELISA, preoperative marker, differential diagnosis, non-invasive, differentiation of benign and malignant tumors, renal tumor, kidney tumor, renal cell carcinoma, oncocytoma, antibody, Vimentin, Vimentin 3, MAPK p38, Mxi-2

Angebot Anbieter-Website


Kontakt | Geschäftsstelle

TechnologieAllianz e. V.
Christiane Bach-Kaienburg
(Geschäftsstellenleiterin)

c/o PROvendis GmbH
Schloßstr. 11-15
D-45468 Mülheim an der Ruhr